EMBRACA Trial in HER2 Metastatic Breast Cancer
Neelima Denduluri MD, Associate Professor, US Oncology Research, Virginia Cancer Specialists shares the results of the phase III EMBARCA trial that compares the efficacy and safety of talazoparib (TA...
Author: obr
Added: 06/26/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2019 Category: Cancer & Oncology Source Type: podcasts
KEYNOTE-062: Pembrolizumab in HER2-, PD-L1 Positive Advanced Gastric Cancer
Thomas A. Abrams Senior Physician and Assistant Professor of Medicine at Harvard Medical School tells us his<br />thoughts on KEYNOTE-62. This is investigating pembrolizumab in HER2, PD-L1 positive advanc...
Author: obr
Added: 06/25/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 25, 2019 Category: Cancer & Oncology Source Type: podcasts
MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
Scott Koenig discusses the data on the Phase 3 SOPHIA study.<br /><br />About MacroGenics, Inc.<br /><br />MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative mo...
Author: Annual-Meeting
Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts
Pembrolizumab, Trastuzumab, Capecitabine & Oxaliplatin In HER2+ mEGA
David Ilson, MD, PhD Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, Discusses Pembrolizumab, Trastuzumab, Capecitabine & Oxaliplatin...
Author: obr
Added: 02/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - February 6, 2019 Category: Cancer & Oncology Source Type: podcasts
HER2 Mutation Positive NSCLC [720p]
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
Author: cancergrace
Added: 10/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 11, 2018 Category: Cancer & Oncology Source Type: podcasts
PI3-Kinase Inhibitors Do Not Work in Tumor Agnostic Way | Targeted Therapeutics Toward HER2 Do Not Always Work
Edward L. Nelson, MD, UC Irvine Health talk about PI3-Kinase Inhibitors Do Not Work in Tumor Agnostic Way | Targeted Therapeutics Toward HER2 Do Not Always Work at MOASC 2018<br />
Author: moasc
Added: 08/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 23, 2018 Category: Cancer & Oncology Source Type: podcasts
The MONALEESA-3 study in HR+/HER2- advanced breast cancer
Douglas W. Blayney, MD, explains the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer
Author: obr
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
the PERSEPHONE trial in early HER2+ breast cancer
Neelima Denduluri, MD, shares the results of the PERSEPHONE trial in early HER2+ breast cancer mean that 6 months of trastuzumab can be given rather than 12 months in the adjuvant setting
Author: obr
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
The MONALEESA-3 study in HR+/HER2- advanced breast cancer
Neelima Denduluri, MD, discusses the significance of the improvement in the PFS fulvestrant +ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer
Author: obr
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
MONALEESA-3 study in HR+/HER2- advanced breast cancer
Douglas W. Blayney, MD, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, on the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONAL...
Author: obr
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
PERSEPHONE: 6 vs. 12-month adjuvant trastuzumab in early breast cancer
Trastuzumab has revolutionized the treatment of HER2+ breast cancer; however, the benefit of a longer duration of this therapy is uncertain. The PERSEPHONE trial (ISRCTN52968807) looked at the efficac...
Author: VJOncology
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Results of the TAILORx study are practice changing
Sara M. Tolaney, MD, MPH, talks about whether the results of the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients are practice changing at ASCO 2018.
Author: obr
Added: 07/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 19, 2018 Category: Cancer & Oncology Source Type: podcasts
The TAILORx study
Sara M. Tolaney, MD, MPH, talks about the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients, means endocrine therapy alone is similar in efficacy to chemoendoc...
Author: obr
Added: 07/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 19, 2018 Category: Cancer & Oncology Source Type: podcasts
Outcomes of the MONARCH 2 study
Sara M. Tolaney, MD, MPH shares the MONARCH 2 study in pre and peri-menopausal ER+, HER2- breast cancer patients at ASCO 2018.
Author: obr
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Beyond APHINITY: What Now After Pivotal Breast Cancer Trial?
Dr Kathy Miller speaks with APHINITY ' s principal investigator about whether survival in HER2+ disease can be pushed even further. (Source: Medscape Oncology)
Source: Medscape Oncology - February 15, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
